Homepage NewsNews HighlightRAG-17 Ractigen Announces Positive Clinical Data for RAG-17 in ALS-SOD1 Treatment from Investigator-Initiated Trial NANTONG and SUZHOU, China, Sep.10, 2024 — Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to…ractigenSeptember 10, 2024
News Highlight Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)…ractigenMarch 3, 2023
